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Abstract
In response to a meal, Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) are released
from gut endocrine cells into the circulation and interact with their cognate G-protein coupled receptors (GPCRs). Receptor
activation results in tissue-selective pleiotropic responses that include augmentation of glucose-induced insulin secretion
from pancreatic beta cells. N-glycosylation and receptor oligomerization are co-translational processes that are thought to
regulate the exit of functional GPCRs from the ER and their maintenance at the plasma membrane. Despite the importance
of these regulatory processes, their impact on functional expression of GIP and GLP-1 receptors has not been well studied.
Like many family B GPCRs, both the GIP and GLP-1 receptors possess a large extracellular N-terminus with multiple
consensus sites for Asn-linked (N)-glycosylation. Here, we show that each of these Asn residues is glycosylated when either
human receptor is expressed in Chinese hamster ovary cells. N-glycosylation enhances cell surface expression and function
in parallel but exerts stronger control over the GIP receptor than the GLP-1 receptor. N-glycosylation mainly lengthens
receptor half-life by reducing degradation in the endoplasmic reticulum. N-glycosylation is also required for expression of
the GIP receptor at the plasma membrane and efficient GIP potentiation of glucose-induced insulin secretion from the INS-1
pancreatic beta cell line. Functional expression of a GIP receptor mutant lacking N-glycosylation is rescued by co-expressed
wild type GLP1 receptor, which, together with data obtained using Bioluminescence Resonance Energy Transfer, suggests
formation of a GIP-GLP1 receptor heteromer.
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Introduction
The hormones Glucose-dependent Insulinotropic Polypeptide
(GIP) and Glucagon-like Peptide-1 (GLP-1) are released from gut
endocrine cells into the circulation, in response to food ingestion.
These peptide hormones act on specific G-protein coupled
receptors (GPCRs), located in multiple tissues [1,2], including
the pancreatic b cell where both GIP and GLP-1 exert their
actions by augmenting glucose-induced insulin secretion.
As for other intrinsic cell surface proteins and GPCRs [3,4], the
GIP and GLP-1 receptors (GIPR; GLP-1R) are synthesized in the
rough endoplasmic reticulum and likely pass through various steps
of post-translational modifications and quality control to ensure
delivery of a correctly folded form to the cell surface. N-
glycosylation is a key process that regulates exit of many GPCRs
from the ER and delivery to the plasma membrane [4,5,6].
However, the influence of these processes on GIPR and GLP-1R
expression and function has not been comprehensively studied.
Both GIPR and GLP-1R are expressed as glycoproteins in
native tissues [7,8,9] implying that N-glycosylation plays a role in
their function and/or cell surface expression. Indeed, treatment
with tunicamycin, a fungicide that inhibits N-glycosylation,
concentration-dependently reduced the number of GLP-1 binding
sites and GLP-1-induced cAMP production in the RINm5F cell
line, suggesting that N-glycosylation is important for functional
surface expression [10]. The impact of N-glycosylation on GIPR
surface expression or on GIP and GLP-1 potentiation of glucose-
induced insulin secretion remains unexplored. Like all family B
GPCRs, both GIPR and GLP-1R possess a large leucine-rich
extracellular N-terminus with several potential sites for N-
glycosylation [11,12], but the extent to which each site is used
and their individual impact on receptor function is not known.
Although able to function as monomers [13,14,15], GPCRs
have been suggested to exist as homo- or hetero-oligomeric
structures that influence cell surface expression and function
[3,5,16]. However, whether oligomerization occurs among all
GPCRs is unclear and has been intensely debated [5,6,17]. Studies
using Bioluminescence Resonance Energy Transfer (BRET)
support homomeric association of the GIPR [18] as well as
heteromerization of the GLP1 and secretin receptors [19].
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32675However, self-association of the GLP1R or close associations
between the structurally-related GIPR and GLP1R have not been
demonstrated; this is potentially critical given the overlap of GIPR
and GLP1R expression and function in tissues such as the
endocrine pancreas.
In this study, we examined N-glycosylation of the incretin
receptors, GIPR and GLP-1R. To establish the extent to which
each of the putative sites are N-glycosylated and their impact on
function, we have carried out a mutational analysis of the N-
terminus of the human GIPR and GLP-1R and examined cell
signaling and surface expression using various approaches. Our
data support a critical and, in the case of the GIPR, essential role
for N-glycosylation in functional cell surface expression. Further-
more, we show that N-glycosylation is required for efficient GIP
potentiation of glucose-induced insulin secretion from the
pancreatic b-cell line, INS-1. Finally, we demonstrate that close
associations of co-expressed GIPR and GLP1R occur, which act to
restore functional expression of the GIPR that is otherwise
abolished by the lack of N-glycosylation, suggesting the formation
of receptor heteromers.
Materials and Methods
Plasmids and Mutagenesis
Human GLP1R cDNA was purchased from GeneCopoeia
(OmicsLink Expression Clone EX-A0510-M02). Overlapping
PCR mutagenesis was used to remove the stop codon and add
common restriction sites in order to insert GLP1R cDNA into
pcDNA3.1-V5 (Invitrogen Corp) such that the V5 epitope was
expressed on the C terminal end of the receptor (GLP1R-V5). The
human GIPR was purchased from Addgene (plasmid 14942,
kindly donated by B Thorens) [20]. Overlapping PCR mutagen-
esis was used to remove the short form of the receptor and its stop
codon from this plasmid as well as insert common restriction sites
such that the cDNA could be inserted into pcDNA3.1-V5 with the
V5 epitope expressed on the C terminal end of the receptor
(GIPR-V5). For N-terminally HA-tagged constructs, overlapping
PCR mutagenesis was used to insert the HA epitope (YPYDVP-
DYA) directly downstream of the GIPR and GLP1R putative
signal peptide sequences on their N-termini. Quickchange PCR
mutagenesis (Stratagene) was used to make all glycosylation point
mutations in both V5-tagged and HA-tagged GIPR and GLP1R
constructs. For BRET constructs, pGFP-N and pRLuc-N vectors
(PerkinElmer), along with GIPR-V5 and GLP1R-V5 were
digested using common restriction sites such that either GFP or
Renilla Luciferase (RLuc) fusion proteins were expressed in frame
on the C-termini of both receptors. All tagged constructs were
tested for functionality using cAMP assays (data not shown). The
ion channel HCN2-GFP was utilized as a control, having been
tested functionally in a previous study [21].
Cell Culture and Expression
CHO-KI cells (American Type Culture Collection) were
maintained in Ham’s F-12 medium (Invitrogen Corp) supple-
mented with 50 ug/ml penicillin/streptomycin (Invitrogen Corp)
and 10% fetal bovine serum (Sigma-Aldrich) and incubated at
37uC with 5% CO2. After 24 h, once cells were approximately
80% confluent, they were transiently transfected with mammalian
expression vectors encoding tagged wild type or mutant receptors
using FuGene6 transfection reagent (Roche Diagnostics).
Tunicamycin treatment
Three mg of cDNA were used for transfection in 50 mm dishes.
Six hours after transfection, tunicamycin (5 mg/ml) (Santa Cruz
Biotechnology Inc) or DMSO was added to cells, which were then
incubated overnight. Cells were then lysed for 30 minutes on ice
with radioimmunoprecipitation assay buffer (RIPA buffer: 50 mM
Tris at pH 8.0, 1% Nonidet P-40, 150 mM NaCl, 1 mM EDTA,
1 mM PMSF, 2 mM each Na3VO4 and NaF, and 10 mg/ml each
aprotinin, pepstatin, and leupeptin). 20 mg of protein was loaded in
10% SDS-PAGE gels.
Cell Surface Biotinylation
Three mg of cDNA were used for transfections in 50 mm dishes.
24 hours after transfection, cells were washed twice with 16PBS
(pH 8.0), then 1 ml Versene (Invitrogen Corp) was added to
detach cells. Cells were collected and washed twice with 16PBS.
300 ml of 5 mM Sulfo-NHS-SS-Biotin (Thermo Scientific) was
added to cells for 45 minutes at room temperature. Cells were
washed with 16PBS supplemented with 100 mM glycine to
quench biotin reaction. Cells were then resuspended in RIPA
buffer and lysed on ice for 30 minutes followed by centrifugation
to collect supernatant. 100 mg of biotinylated lysate were added to
100 ml of 50% streptavidin-conjugated agarose beads (Sigma-
Aldrich), and bead-lysate mix was incubated overnight at 4uC with
rotation. Beads were washed with 16 PBS supplemented with
0.1% NP-40, and incubated with Laemmli sample buffer
supplemented with 1 mM DTT for 1 hour at room temperature,
then loaded in 10% SDS-PAGE gels.
Western Blotting
Proteins separated on SDS-PAGE gels were transferred onto
PVDF membranes using the i-Blot transfer device (Invitrogen
Corp). Membranes were then blocked with 5% non-fat milk in
TBST overnight at 4uC. Mouse-anti V5 (1:1000, Invitrogen Corp)
was added to the membrane and incubated for 2.5 hours at room
temperature. Blots were washed three times in TBST, followed by
addition of 1:3000 anti-mouse secondary antibody conjugated to
horseradish peroxidase (Santa Cruz Biotechnology Inc) for 1 hour
at room temperature. Blots were washed in TBST, followed by
chemiluminescence detection.
ELISA Assays
Three mg of cDNA were used for transfections in 50 mm dishes.
24 hours after transfection, cells were seeded into 96-well assay
plates (Corning Inc) at a density of approximately 100,000 cells per
well. After 24 hours, cells were fixed with 4% paraformaldehyde
and antigen detected with mouse-anti HA primary antibody
(1:1000, Sigma-Aldrich), followed by anti-mouse-HRP conjugated
secondary antibody (1:1000 Santa Cruz Biotechnology Inc) and
SuperSignal ELISA Femto Maximum Sensitivity Substrate
(Thermo Scientific). Signals were detected using the Victor 3 V
plate reader (PerkinElmer). Each condition was carried out in
triplicate, and data was collected from a minimum of 5 independent
transfections. Mutants and wild type receptor data were compared
using one-way ANOVA followed byDunnett’s multiple comparison
tests (Graph Pad Prism).
TR-FRET cAMP assays
For transfections in 50 mm dishes, 0.5 mg of cDNA was used.
24 hours after transfection, cells were rinsed with 16 HBSS
(Invitrogen Corp), detached with 1 mL Versene (Invitrogen Corp),
then resuspended at a density of 6000 cells per 5 ml in stimulation
buffer, pH 7.4 (16HBSS supplemented with 5 mM HEPES buffer,
0.1% BSA and 0.5 mM IBMX). Both GLP-1 7–36 amide and GIP
peptides (Sigma-Aldrich) were diluted in stimulation buffer. Assay
was then performed according to LANCE TR-FRET cAMP assay
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PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e32675Figure 1. Consensus sites for N-glycosylation are found in the N-termini of the closely related human GIPR and GLP-1R. The amino
acid sequences for human GIPR and GLP-1R (A) and three mammalian species for each receptor (B) were aligned by ClustalW. Shading was carried out
using Boxshade on the Swiss EMBnet node web site (www.ch.embnet.org/software/BOX_form.html). Amino acids highlighted in black represent
complete identities, whereas those highlighted in gray represent conserved identities. Arrows are placed above or below putative N-glycosylation sites
and the numbers correspond to their location in the human sequences. In ‘‘A’’, the black and gray arrows correspond to the Asn (N) residues in the
human GIPR and GLP-1R, respectively. In ‘‘B’’, the gray arrow corresponds to an Asn site found in the rodent sequences but not the human sequence.
doi:10.1371/journal.pone.0032675.g001
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Peptide stimulation of cells was carried out for 30 minutes and
detection for 1 hour at room temperature, followed by fluorescence
detection on a Victor 3 V plate reader (PerkinElmer), according to
LANCE protocol parameters. RFU values generated at each dose
were subtracted from values obtained using untransfected cells. Data
for cAMP curves were fitted to the sigmoidal dose-response equation
(Graph Pad Prism) and EC50 values for individual experiments were
calculated. Each curve was generated from at least 5 independent
transfectionsand EC50valueswere compared towildtypeusing one-
way ANOVA, followed by Dunnett’s multiple comparison tests.
Half-life Assay
Twenty-four hours after transfection of V5-tagged constructs,
cycloheximide (Sigma-Aldrich) was added to cells in F-12 media
with serum to a final concentration of 100 ug/ml. Cells were then
lysed at times 0 h, 2 h, 4 h and 8 h after addition of cycloheximide.
DMSO was added to transfected cellsasa negativecontrol. 30 ug of
protein lysate were loaded into SDS-PAGE gels and western blots
were performed as described.
Immunocytochemistry, Imaging and Pearson
Correlations
Forty-eight hours after transfection, CHO cells were rinsed with
PBS and fixed with 2% paraformaldehyde in PBS for 5 min. Fixed
cells were washed twice with PBS, permeabilized for 10 min using
0.2% Triton X-100, then blocked with 10% normal goat serum
(NGS) for 10 min. After one wash with PBS containing 1% NGS,
cells were incubated with primary antibodies for 1 h at room
temperature. Anti-HA (Sigma-Aldrich) mouse monoclonal anti-
body was used at a dilution of 1:500 and rabbit anti-calnexin
(Sigma-Aldrich) at a dilution of 1:100. Cells were subsequently
washed with PBS three times and incubated with Alexa-555-
tagged anti-mouse and Alexa-488-tagged anti-rabbit secondary
antibodies (Molecular Probes, Inc.) at a dilution of 1:1500 in PBS
with 1% NGS for 1 h at room temperature in the dark. After
washing three times in PBS, coverslips were rinsed in H2O and
mounted on slides using Gel Mount (Sigma-Aldrich). Cells were
visualized using a Zeiss Axiovert 200 fluorescence microscopy with
an Apotome structured illumination module and with a 663 oil
immersion objective lens. Results reported represent three
transfections for each set of the imaging experiments described.
To correlate intensities of fluorescence for each pair of proteins,
Pearson correlation coefficients were calculated from captured
images of individual cells as determined by the following equation
(Axiovision User Guide),
((GVC1{MVC1)|(GVC2{MVC2))7
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ X
(GVC1{MVC1)
2|
X
(GVC2{MVC2)
2
q
where GV represents Gray Value, MV is Mean Value, and C is
channel.
The values range from 21t o+1, representing an increasing
correlation of the intensities measured in two channels. In other
words, the Pearson correlation coefficient describes the interde-
Figure 2. All putative N- glycosylation sites found on the N-termini of human GIPR and GLP-1R are used. Western Blots of C-terminally
V5-tagged GIPR (A) and GLP-1R (B) and respective tagged mutant receptors in which putative N-glycosylation sites were substituted by glutamine, as
indicated. Blots were probed with mouse monoclonal antibody against the V5 epitope. For both receptors, blots were also probed with a rabbit
polyclonal antibody for actin to control for loading. Lanes marked with ‘‘+’’ were treated with tunicamycin, and ‘‘2’’ with DMSO control. Untagged
GIPR and GLP-1R are used as negative controls for non-specific antibody binding. Upper and lower arrows indicate the molecular weights for the
heaviest bands and lightest bands. The predicted molecular weight for the immature form of GIPRV5 is 57.7 kDa and of GLP-1RV5 is 57.4 kDa.
doi:10.1371/journal.pone.0032675.g002
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proteins of interest throughout a cell.
Culture of INS-1 Cells
INS-1 (clone 831/12) cells were obtained from Dr. C.B.
Newgard (Duke University) [22]. Cell lines were maintained at
37uC with 5% CO2. Cells were grown in RPMI-1640 medium
containing 11 mM glucose, supplemented with 10% fetal bovine
serum (Cansera, Rexdale ON), and penicillin/streptomycin,
supplemented with 10 mM HEPES (pH 7.4), 1 mM sodium
pyruvate, 2 mM glutamine and 50 mM b-mercaptoethanol.
Saturation Binding Analysis in INS-1 Cells
INS-1 cells were plated in 24 well plates at a density of 5610
5
cells/well and allowed to grow for 24 hours, then treated with
1 mg/ml tunicamycin for 24 hours. Saturation binding experi-
Figure 3. N-glycosylation more strongly impacts cell surface expression of the GIPR than the GLP-1R. Plots of cell surface luminescence
(A), whole cell luminescence (B) and their ratio (C) from cells expressing N-terminally HA-tagged GIPR (left) and GLP-1R (right). All constructs were
assayed in triplicate from 4–5 separate transfections. Each group of triplicates was corrected for background luminescence from untransfected cells
and from cells treated with only secondary HRP-conjugated antibody for each transfected condition. Asterisks represent significance (P,0.05) as
determined using a one-way ANOVA, followed by Dunnett’s multiple comparison tests, comparing mutant constructs to tagged wild type receptors.
doi:10.1371/journal.pone.0032675.g003
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analyzed using a one site model for GIP binding and then fitted to
a curve with the equation:
Y~Bmax|X=(Kd+X)
where Bmax is the binding obtained when cells are saturated with
125I-GIP, and Kd is the concentration of
125I-GIP required to
reach half-maximal binding. The number of receptors on each cell
was determined using the specific activity of the radiolabel and
Avogadro’s number.
Insulin Release from INS-1 Cells
Cells were plated into 24 well plates (5610
5 cells/well) and
grown for 24 hours. Cells were treated with 1 mg/ml tunicamycin
for 24 hours, followed by incubation with either 5.5 mM or
11 mM glucose with or without 50 nM GIP for 30 minutes at
37uC, then assayed for insulin content using RIA. The means were
compared using two-tailed ANOVA followed by Dunnett’s
multiple comparison tests.
BRET
2 assays
Here, 0.5 mg of RLuc-tagged construct and 0.5–3 mg of GFP-
tagged construct cDNA were used for transfections in 50 mm
dishes. BRET
2 experimental methods were carried out according
to our previously published protocol [24]. 24 hours after
transfection, cells were rinsed with DPBS (Invitrogen Corp) and
treated with 1 mL of 0.5% trypsin-EDTA (Invitrogen Corp). 3 ml
of HAM’s F12 media containing FBS was added; cells were
centrifuged at 8006g and resuspended in BRET
2 Buffer (DPBS
supplemented with 2 mg/ml Aprotinin). Approximately 100,000
cells were distributed into 96-well white optiplates (PerkinElmer).
Using a Victor 3 V plate reader (PerkinElmer), expression of GFP-
tagged constructs was assessed by directly exciting GFP with a
400–410 nm excitation filter. Expression of Rluc-tagged constructs
was assessed using luminescence values obtained in the BRET
2
assay. For BRET
2 measurements, DeepBlueC substrate (Perki-
nElmer) was added to the cells at a final concentration of 5 mM,
and Rluc emission was measured through a 370–450 nm filter.
Resulting GFP emission was in turn measured with a 500–530 nm
filter. All raw data were corrected by subtracting the BRET
2 ratio
and GFP/Rluc values determined from cells transfected with only
RLuc-tagged construct (plotted at 0,0). Data were fitted to a single
binding site equation by non-linear regression (GraphPad Prism).
Results
Multiple N-glycosylation consensus sites are present and
utilized on the N-termini of the human GIPR and GLP-1R
The human GIPR and GLP-1R possess large N-terminal
domains containing 2 and 3 putative N-glycosylation sites,
respectively, as predicted by the NXS/T consensus sequences
for N-glycosylation where X?Proline. The locations of the two
putative sites in the GIPR correspond closely to those of the GLP-
1R (Fig. 1A), suggesting some evolutionary conservation of N-
glycosylation between them. The human GLP-1R has an
additional N-glycosylation site (N115), the closest to the first
transmembrane domain, which appears as an insertion when
aligned with the GIPR sequence. As for the human GLP-1R, the
mouse and rat GIPR have three putative N-glycosylation sites on
their N termini (Fig. 1B). However, the location of the third site in
the rodent GIPR does not correspond to that in the GLP-1R, but
is instead found between the two conserved sites (N62 and N77).
Here, we focus on N-glycosylation of sites within the N-termini of
the human GIPR and GLP-1R.
To determine whether each of the putative N-glycosylation sites
is utilized, we individually and progressively mutated all sites in the
human GIPR and GLP-1R from Asn to Gln and performed
western blotting to determine whether corresponding shifts in
molecular weight were produced. Both wild type receptors
migrated at higher molecular weights than when treated with
tunicamycin, an antibiotic that selectively inhibits oligosaccharyl-
transferase to block the addition of N-acetylglucosamine onto
dolicho-phosphate (Fig. 2A,B). Furthermore, mutation of all
putative N-glycosylation sites yielded single bands that migrated
at lower weights, unaltered by tunicamycin. The molecular
weights of receptors with single site mutations were reduced
compared to wild type GIPR and GLP-1R, but were still greater
than those following treatment with tunicamycin. Together, these
data suggest that all putative sites in both receptors are
glycosylated when expressed in CHO cells.
Figure 4. N-glycosylation increases the presence of cell surface isoforms of GIPR and GLP-1R protein. Western Blots of biotinylated cell
surface protein (upper) and total protein lysate (middle) for V5-tagged GIPR (left) and GLP-1R (right). Upper and middle blots were probed with a
mouse monoclonal antibody to the V5 epitope while the lower blots were probed with a rabbit polyclonal antibody to actin as a loading control.
Note the absence of biotinylated protein in the lane containing N62,77Q-GIPR but not in the lane containing N63,82,115Q-GLP-1R.
doi:10.1371/journal.pone.0032675.g004
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absence of tunicamycin for most constructs, likely representing the
presence of both core and complex glycosylated species. A second
band of higher molecular weight is present in tunicamycin-treated
GIPRs, and is also present in N62,77Q-GIPR lanes on blots with
longer exposure times (data not shown), suggesting the presence of
a second unglycosylated form. Treatment of lysates with PNGase,
which cleaves sugar moieties from Asn residues, produced band
patterns identical to those using tunicamycin (data not shown), as
expected.
N-glycosylation promotes cell surface expression of GLP-
1R and is required for surface expression of GIPR
To examine the influence of N-glycosylation on cell surface
expression, GIPR and GLP-1R were quantified at the plasma
Figure 5. Sensitivity and efficacy of GIP and GLP-1 actions on cAMP production in CHO cells are enhanced by N-glycosylation of
their receptors. Plots of Relative Fluorescence Units (RFU) versus log of concentration of GIP (A) or GLP-1 (B). RFU values were determined by FRET
assay which was carried out using CHO cells expressing GIPR or GLP-1R constructs as indicated. Forskolin was used to control for variations in total
cell number. Mean data 6 SE (performed in duplicate for an n=5 separate transfections) at each ligand concentration were plotted, converted to a
logarithmic scale, and fitted using a sigmoidal dose-response curve.
doi:10.1371/journal.pone.0032675.g005
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constructs. When individual sites were mutated, a significant
decrease in GIPR but not in GLP-1R cell surface expression was
observed when compared to wild type receptors (Fig. 3A). With all
N-glycosylation sites missing, surface expression of GLP-1R was
still detected, whereas GIPR cell surface expression was virtually
abolished. This trend was maintained when cell surface protein
was calculated as a fraction of whole cell protein (Fig. 3C). Thus,
the relative reduction in mutant surface protein expression was not
predominantly a result of the observed decreases in intracellular
protein (Fig. 3B).
To complement our findings from cell surface ELISA, we
examined receptor surface protein using biotinylation assays. Not
surprisingly, the intensities of the bands in western blots for both
receptors at the cell surface and total lysates showed patterns that
reflected those obtained by cell surface ELISA (Fig. 4). For both
GIPR and GLP-1R lacking any N-glycosylation sites, the total
protein (Fig. 4, lower protein lysates) was somewhat reduced
whereas the cell surface protein (Fig. 4, upper blot) was more
strongly decreased (N63,82,115Q-GLP-1RV5) or absent
(N62,77Q-GIPRV5). Interestingly, there was a more pronounced
reduction in amount of cell surface protein for N77Q-GIPR when
compared to the N62Q-GIPR, again consistent with the findings
from ELISA (Fig. 3A).
The blots of biotinylated protein also reveal multiple forms of
wild type incretin receptors at the cell surface, likely representing
variably N-glycosylated proteins. Single and double mutations of
the GLP-1R, as well as the N62Q-GIPR, were also found at the
cell surface in multiple forms. In contrast, only one immature form
was observed for the N77Q-GIPR and the GLP-1R lacking all N-
glycosylation sites.
Sensitivity and efficacy of the cAMP response of the GIPR
and GLP-1R to their natural ligands are augmented by N-
glycosylation at a single site
To investigate the role of N-glycosylation in receptor function,
cAMP production was measured in CHO cells expressing GIPR
or GLP-1R using a FRET-based assay. For both wild type
receptors, increases in cAMP levels were observed in response
to increasing concentrations of their respective ligands (GIP or
GLP-1; Fig. 5). Elimination of all receptor N-glycosylated sites
abolished cAMP production by GIP but not by GLP-1. This is not
surprising given the observed absence of GIPR but not GLP-1R at
the cell surface.
In all instances, with the exception of N77Q-GIPR, removal of
a single glycosylation site on either receptor resulted in
concentration-response curves similar to those of corresponding
wild type receptors (Fig. 5A and B, upper). Furthermore,
N63,82Q-GLP-1R displayed concentration-response curves that
did not differ from wild type GLP-1R (Fig. 5B, lower). In contrast,
the EC50 values for N63,82,115Q-GLP-1R and N77Q-GIPR
were significantly greater than those determined for the wild type
receptors (Table 1). The amplitude of the cAMP response was also
reduced for N63,82,115Q-GLP-1R.
The rightward shift in concentration-response curves is
observed in the same two mutants that displayed the lowest
protein expression on the cell surface (see Fig. 3), suggesting a
connection between the quantity of receptors expressed at the
Table 1. Mean EC50 values and amplitude of responses for cAMP concentration-response curves in Figure 5.
A.
EC50 (M) Amplitude (RFU)
Mean S.E. P Value Mean S.E. P Value
GIPR-V5 8.2610
211 1.7610
211 -2 . 2 610
4 1.3610
3 -
N62Q-V5 1.0610
210 1.5610
211 P.0.05 2.7610
4 3.3610
3 P.0.05
N77Q-V5 3.1610
29 1.1610
29 P,0.01 2.2610
4 6.5610
2 P.0.05
N62,N77Q - - - 8.0610
3 1.4610
3 P,0.01
B.
EC50 (M) Amplitude RFU
Mean S.E. P Value Mean S.E. P Value
GLP1R-V5 4.1610
210 1.2610
210 -1 . 7 610
4 3.7610
3 -
N63Q-V5 6.3610
210 1.4610
210 P.0.05 1.9610
4 3.9610
3 P.0.05
N82Q-V5 7.1610
210 2.6610
210 P.0.05 1.9610
4 2.6610
3 P.0.05
N115Q-V5 7.2610
210 1.1610
210 P.0.05 2.0610
4 4.2610
3 P.0.05
EC50 (M) Amplitude RFU
Mean S.E. P Value Mean S.E. P Value
GLP1R-V5 2.2610
210 1.1610
210 -2 . 9 610
4 9.0610
2 -
N63,82Q-V5 5.8610
210 2.9610
210 P.0.05 2.8610
4 1.9610
3 P.0.05
N63,82,115Q-V5 2.7610
29 6.8610
210 P,0.01 2.0610
4 2.0610
3 P,0.01
EC50 values were determined for each individual experiment, using a sigmoidal dose-response equation. Compared to wild-type receptors, the EC50 values for N77Q-
GIPR and N63,82,115Q-GLP-1R were significantly right shifted, as shown by a one-way ANOVA analysis followed by Dunnett’s multiple comparison test. The changes in
RFU values for the N62,77Q-GIPR were small and could not be accurately fitted. The amplitude of response was calculated by subtracting the lowest RFU values from
the highest for each individual experiment.
doi:10.1371/journal.pone.0032675.t001
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shift could, however, be reflective of impaired function, and/or
coupling to adenylyl cyclase, of misfolded surface-localized
receptors.
The right-shift of the N77Q-GIPR, but not the N62Q-GIPR
concentration-response curve suggests that the former site exerts
functional dominance. Interestingly, cell surface ELISA data also
suggests that site N77 plays a stronger role in regulating cell
surface expression (see Fig. 3). In other intrinsic membrane
proteins of the plasma membrane, non-uniformity among multiple
sites has been noted [25,26,27].
N-glycosylation of incretin receptors prevents
degradation in the endoplasmic reticulum
First,theamountofreceptorproteinthatassociatedwithcalnexin
in the endoplasmic reticulum was quantified, by correlating the
intensity of receptor-calnexin co-immunolabelling (Fig. 6A). For the
GLP receptors, the wild type showed a low level of correlation
whereas for the complete glycosylation-deficient mutant the
correlation was much higher, at just under 50% (Fig. 6A, lower).
For the GIP receptor, an even greater contrast was observed
between the wild type receptor, which showed almost no
correlation, and the complete glycosylation-deficient mutant in
Figure 6. N-glycosylation-deficient incretin receptors are retained in the endoplasmic reticulum and degraded to a greater extent
than wild type. (A) Co-localization of both wild type and N-glycosylation-deficient receptors with calnexin shown in photographs (left); the
correlation of their intensities is shown in the bar graphs (right). (B) Western blots showing wild type and N-glycosylation-deficient incretin receptors
at indicated time points following cycloheximide administration to CHO cells expressing each receptor.
doi:10.1371/journal.pone.0032675.g006
Cell Surface Expression of Incretin Receptors
PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e32675which correlation is about 80% (Fig. 6A, upper) Together, the data
suggest that the reduction in glycosylation- deficient mutants at the
cell surface is mainly due to an increase in ER retention and
degradation. These data are also consistent with a larger role for N-
glycosylation of the GIP receptor than for the GLP-1 receptor.
To address whether mis-folding and ER degradation is reduced
by N-glycosylation, we used western blotting to determine the
stability of the glycosylation deficient receptors following cyclo-
heximide application. The rate of disappearance of glycosylation
deficient receptors over time was increased compared to that of
wild type receptors (Fig. 6B). Moreover, even at time=0, the
overall level of glycosylation-deficient receptors is much lower than
that of wild-type receptors; this is especially apparent for the GIP
mutant receptor.
N-glycosylation maintains cell surface GIP receptor
number and GIP-potentiated insulin secretion in INS-1
cells
We next examined the role of GIPR N-glycosylation in
regulating ligand binding, surface receptor number and insulin
secretion. We chose the INS-1 b-cell line, which reflects a similar
physiology to that of native b-cells, including GIP-induced
potentiation of insulin secretion in the presence of glucose [22].
INS-1 cells were treated with tunicamycin and specific binding of
GIP was measured using a radioactive binding assay. Tunicamy-
cin lowered cell surface
125I-GIP binding, which, at saturating
levels, corresponded to a 70% decrease in cell surface GIPR
number (Fig. 7A). The dissociation constants (Kd) of GIP from the
surface of these cells did not significantly differ between the control
(455650 pM) and tunicamycin (3456100 pM) treated cells,
suggesting that ligand binding affinity was not impaired by
removal of N-glycosylation.
To investigate the impact of N-glycosylation on GIPR incretin
response, GIP-stimulated insulin secretion was measured in
tunicamycin-treated and untreated INS-1 cells. Without tunicamy-
cin, GIP (50 nM) significantly and strongly potentiated insulin
secretion,whenincreasingglucosefrom5.5 mMto11 mM(Fig.7B).
Tunicamycin treatment, however, blunted the incretin effect of GIP.
Tunicamycin did not significantly modify insulin secretion in
response to glucose alone, suggesting that GIP potentiation was
eliminated specifically by the inhibition of N-glycosylation. These
Figure 7. N-glycosylation regulates GIP receptor number and GIP-potentiated insulin secretion in INS-1 cells. (A) Plot of specific
binding versus concentration of
125I-GIP saturation carried out in INS-1 cells with or without 1 mg/ml tunicamycin. Data were fitted with a non-linear
regression equation assuming a single binding site (GraphPad Prism). Control cells expressed an average of 24436400 GIP receptors on the cell
surface (Kd 455650 pM), whereas tunicamycin-treated cells expressed 760670 GIP receptors on the cell surface (Kd 3456100 pM). (B) Plot of insulin
release in response to glucose and/or GIP, from INS-1 cells with or without 1 mg/ml tunicamycin. Data are expressed as mean 6 SEM, n=4 separate
experiments. Asterisk indicates a significant increase in insulin release compared to basal conditions without addition of 50 nM GIP (P,0.05), as
determined using two-way ANOVA followed by Bonferroni post-tests.
doi:10.1371/journal.pone.0032675.g007
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PLoS ONE | www.plosone.org 10 March 2012 | Volume 7 | Issue 3 | e32675Figure 8. Function but not cell surface expression of N62,77Q-GIPR is rescued by co-expression of wild type GLP1R. (A) Plots of
Relative Fluorescence Units (RFU, indicative of cAMP production) versus log of concentration of GIP. RFU values were determined by FRET assay
which was carried out using cells expressing GIPR and GLP1R as indicated. Forskolin was used to control for variations in total cell number. Mean data
6 SE (n=5 transfections) at each ligand concentration were fit using a sigmoidal dose-response curve. (B) Plots of cell surface (left) and whole cell
(right) luminescence from cells co-expressing N-terminally HA-tagged GIPR and/or GLP1R, as indicated. All constructs were assayed in triplicate from
4–5 separate transfections. Each group of triplicates was corrected for background luminescence from untransfected cells and from cells treated with
only secondary HRP-conjugated antibody for each transfected condition. Pairs of receptors (grouped in brackets), consisting of one HA-tagged
construct and a second untagged construct, were statistically compared by a two-tailed unpaired t-test (p.0.05 for each comparison made).
doi:10.1371/journal.pone.0032675.g008
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do not discount a potential impairment in GIPR function and/or
signal transduction by the deficiency in N-glycosylation.
The function and cell surface expression of a GIPR
mutant completely lacking N-glycosylation is rescued by
close association with the wild type GLP1R
It has been suggested that many GPCRs exist as homo- or
heterodimers and/or higher order oligomers at the cell surface
and, in some cases, this interaction may be initiated during
translation [28,29]. Because the GIPR and GLP1R have a
relatively high level of sequence identity (Fig. 1) and have similar
expression profiles and physiological function, we reasoned that
the GLP1R might form a functional complex with the GIPR. To
test this, we first examined whether cell surface expression and
function of the GIPR mutant lacking N-glycosylation could be
rescued by co-expression with wild type GLP1R. Cyclic AMP
levels were again measured in CHO cells expressing each receptor
construct. In cells expressing N62,77Q-GIPR only, the amount of
cAMP was unchanged from baseline in response to GIP. In
contrast, the levels of cAMP increased in a concentration-
dependent manner by GIP in cells co-expressing N62,77Q-GIPR
along with the wild type GLP1R, although the EC50 value was
right shifted compared to wild type GIPR (Fig. 8A, Table 2).
These results show that functional expression of N62,77Q-GIPR
was rescued by co-expressed wild type GLP1R.
In an attempt to quantify the extent of N62,77Q-GIPR cell
surface rescue by wild type GLP1R, cell surface ELISA was again
used. When the HA-tagged mutant GIPR was co-expressed with
wild type GLP1R, the measured cell surface luminescence was
very low and not significantly altered as compared to co-
expression with the untagged version of itself (Fig. 8B, upper).
Since the amplitude of cAMP responses to GIP were identical for
both wild type GIPR, and mutant GIPR in the presence of
GLP1R, it appears that rescue of a very small amount of the
N62,77Q-GIPR, below the level of detection by cell surface
ELISA, suffices to fully restore activation of adenylate cyclase in
the CHO cell system.
The rescue of only a small fraction of N62,77Q-GIPR to the cell
surfacecould be explainedbya correspondingretention ofwild type
GLP1R by the GIPR mutant. However, this was not the case since
theamountofHA-taggedGLP1R atthecell surfacewasunchanged
by co-expression with N62,77Q-GIPR (Fig. 8B, upper). Moreover,
when co-expressed, the total level of mutant GIPR and wild type
GLP1R were no different than when each was co-expressed with
non-HA tagged versions (Fig. 8B, lower). Therefore, it seems more
likely that functional rescue of the mutant GIPR is due to a low level
of association with the wild type GLP1R, which is below the
detection sensitivity of the ELISA assay.
The low level of association between N62,77Q-GIPR and wild
type GLP1R could be due to the small differences in their primary
sequences, thus potentially limiting interaction between key
regions. To test this, we co-expressed N62,77Q-GIPR with wild
type GIPR and measured cell surface and total protein expression
of both receptor constructs by ELISA. Co-expression of wild type
GIPR did not rescue cell surface expression of its mutant
Figure 9. Cell surface expression of N62,77Q-GIPR is not rescued by co-expression with the wild type GIPR. Plots of cell surface (left)
and whole cell (right) luminescence from cells co-expressing HA-tagged GIPR as indicated. All constructs were assayed in triplicate from 4–5 separate
transfections. Each group of triplicates was corrected for background luminescence from untransfected cells and from cells treated with only
secondary HRP-conjugated antibody for each transfected condition. Pairs of receptors (grouped in brackets), consisting of one HA-tagged construct
and a second untagged construct, were statistically compared by a two-tailed unpaired t-test (p.0.05 for each comparison made).
doi:10.1371/journal.pone.0032675.g009
Table 2. Mean EC50 values and amplitude of response for
cAMP concentration-response curves in Figure 8A.
EC50 (M) Amplitude RFU
Mean S.E. P Value Mean S.E. P Value
GIPR-V5 3.4610
211 1.1610
211 - 2.3610
4 2.8610
3 -
N62,N77Q-V5 - - - 5.0610
3 7.1610
2 P,0.01
GLP1R-V5 - - - 6.3610
3 2.0610
3 P,0.01
GLP1R-
V5+N62,N77Q-V5
1.1610
28 5.2610
29 P,0.0001 1.9610
4 2.3610
3 P.0.05
EC50 values were determined for each individual experiment, using a sigmoidal
concentration-response equation. Compared to wild-type GIPR, the EC50 values
for N62,77Q-GIPR when co-expressed with the wild type GLP1R was
significantly right shifted, as shown by a one-way ANOVA analysis followed by
Dunnett’s multiple comparison test. The changes in RFU values for N62,77Q-
GIPR or the GLP1R were small and could not be accurately fitted. The amplitude
of response was calculated by subtracting the lowest RFU values from the
highest for each individual experiment.
doi:10.1371/journal.pone.0032675.t002
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left). Thus, the extent of receptor homology is not likely a factor for
limiting the amount of cell surface rescue of the mutant GIPR.
The functional rescue of the N62,77Q-GIPR by the wild type
GLP1R nevertheless suggests some form of physical association.
To test for this, we utilized BRET to measure the effects of co-
expressing GFP-labeled forms of GLP1R with RLuc-tagged GIPR
(Fig. 10A). For a negative control, we used GFP-tagged
hyperpolarization-activated channel (HCN2-GFP), a structurally
similar membrane protein that has been shown to localize to the
cell surface and function normally when expressed in CHO cells
[21], but which would not be expected to assemble with either
receptor. We also tested the effects of co-expressing GFP- and
RLuc- labeled GLP1R (Fig. 10B), as well as GFP- and RLuc-
labeled GIPR (Fig. 10C). For all three receptor combinations, the
BRET saturation curves reached higher maximal values than their
respective negative controls. The high values of BRET obtained,
coupled with the rescue of N62,77Q-GIPR function by the wild
type GLP1R, support heteromeric and homomeric associations of
the GIPR and GLP1R.
Discussion
Upon translation of the GIPR or GLP-1R nascent chains in the
endoplasmic reticulum, they become subject to glycosylation at the
Asn residues located in the extracellular N-terminus. We have
Figure 10. BRET values for cells expressing GIPR and GLP1R suggest heteromeric and homomeric associations. Plots of BRET
2 ratio
versus the ratio of GFP/Luc from cells co-expressing RLuc- and GFP-tagged combinations of GIPR, GLP1R and HCN2 channels. (A) Curves from
GIPR+GLP1R (Bmax=0.07360.003) compared to GIPR+HCN2 negative control (Bmax=0.02860.004). (B)C u r v e sf r o mG L P 1 R +GLP1R
(Bmax=0.1560.03), compared to GLP1R+HCN2 negative control (Bmax=0.02960.006). (C) Curves from GIPR+GIPR (Bmax=0.1360.02), compared
to GIPR+HCN2 negative control (Bmax=0.02860.004). Data were collected from at least separate 5 transfections and fit with a non-linear regression
equation assuming a single binding site; they were statistically analyzed using a two-tailedu npaired t test and for all conditions, Bmax was
significantly greater than negative controls, p,0.001.
doi:10.1371/journal.pone.0032675.g010
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either the human GIPR or GLP-1R is expressed in CHO cells. For
both receptors, cell surface expression and/or function were
impaired by removal of N-glycosylation, although the GIPR was
more strongly affected and possessed a single site (N77) that was
dominant. Our results from ELISA experiments suggest that the
decrease in cell surface receptor expression can be attributed to
factors independent of variations in total expression. Our data also
show enhanced ER retention and degredation in the absence of N-
glycosylation, in parallel with disrupted cell surface expression.
Our findings come from expression of CHO cells, which is a
limitation as primary beta-cells are very difficult to transfect and
the low level of GIP and GLP-1 expression makes studies on
endogenous glycosylation very difficult.
Importantly, we found that N-glycosylation regulates GIPR cell
surface expression and the potentiation of glucose-induced insulin
secretion by nanomolar levels of GIP in INS-1 cells. These data
are similar to those obtained with the GLP-1R in RINm5F cells,
where cell surface receptor number and GLP-1-induced cAMP
production are reduced by tunicamycin treatment [10]. Thus, N-
glycosylation maintains a level of GIPR and GLP-1R surface
expression that is critical for downstream signaling and regulation
of insulin secretion. Notably, 30% of the normal total number of
GIP receptors remained after tunicamycin treatment despite an
absence of GIP-potentiation of glucose-induced insulin secretion.
This implies that a threshold number of GIP receptors exist, which
must be surpassed in order to potentiate insulin secretion to a level
that could be measured by our assay. Our findings in CHO cells
suggest that the reduction in cell surface expression in the absence
of N-glycosylation in the INS-1 cells is also due to enhanced
retention and degredation of GIPR in the endoplasmic reticulum.
Basic mechanisms of cell surface trafficking and ER quality control
are conserved among most cells [30,31], but studies in beta cells
are required to determine their precise impact on incretin receptor
cell surface expression and lifespan.
When cAMP was assayed in response to increasing concentra-
tions of ligand, cells containing glycosylation-deficient GLP-1R or
N77Q-GIPR exhibited a right-shifted concentration-response
curve. This could have reflected a direct defect in GIP or GLP-
1 binding to their respective receptors, or to a coupling problem
with the signal transduction machinery. However, our data of
GIP-binding to INS-1 cells, and previous data on GLP-1 binding
to RINm5F cells [10], showed that binding affinity was unaffected
by tunicamycin treatment, whereas the total surface receptor
number was significantly decreased along with potentiation of
insulin secretion. These data are consistent with those in other
studies of bradykinin B2,P 2Y12 ADP, and the type 1a
metabotropic glutamate receptors, which also found that ligand-
binding affinity was unaltered by inhibition of N-glycosylation
[32,33,34]. Thus, the reduction in incretin sensitivity that we
observed is probably due impaired function, and/or coupling to
adenylyl cyclase, of misfolded surface-localized receptors. Alter-
natively, since cell surface expression and, in the case of the
glycosylation-deficient GLP-1R, the maximum cAMP response
were also reduced in concert with sensitivity, it is possible that the
efficiency of coupling to downstream effector molecules such as
adenylyl cyclase correlates with cell surface receptor number. Such
a relationship between EC50 and cell surface number has been
reported for the b2-adrenergic receptor, but the mechanism
underlying this association remains unknown [35,36]. In these
studies, the b2-adrenergic receptor was localized to caveolae to a
lesser extent when cell surface number was reduced; this suggests
that efficient signal transduction requires localization of receptors
to these structures, which contain the necessary machinery for
cAMP production.
The rescue of mutant GIPR function by the wild type GLP1R,
and the close association between the two receptors as measured
by BRET, suggests that they are able to associate in a receptor
complex. According to a recent definition, receptor heteromers are
‘‘composed of at least two functional receptor units with
biochemical properties that are demonstrably different from those
of its individual components’’ [37]. Functional co-assembly is
supported by reduced sensitivity of the rescued GIPR mutant to
GIP when compared to the wild type GIPR, as seen by the right
shift in EC50 for cAMP formation; however, this right shift could
also be explained by a corresponding reduction in number of
mutant receptors at the cell surface, compared to wild type.
Therefore, it remains uncertain as to whether oligomerization of
GIPR and GLP1R produces a receptor complex with unique
properties and, thus, whether a GIP-GLP1 receptor heteromer
exists in our system. We also found that oligomerization may have
been limited between glycosylation-deficient GIPR and the wild
type GLP1R, based on the lack of cell surface rescue. Indeed,
various studies have shown that when N-glycosylation is removed,
regular receptor dimer formation and stability is impaired, thereby
impacting the receptor heteromer’s ability to express at the cell
surface and/or correctly function [38,39,40,41,42]. Studies that
further examine the functional and structural nature of the
association between GLP-1R and GIPR will be required to
determine the complete nature of this association and whether a
true receptor heteromer is formed by them.
Regulation of GIPR and GLP-1R by N-glycosylation may have
important implications for type 2 diabetes (T2DM). There is a
reduced incretin effect in human T2DM patients [43], which has
been attributed to reduced ß-cell responsiveness to GIP [44] and,
to a lesser extent, GLP-1 [45]. Moreover, reduced incretin
receptor expression has been observed in animal models of T2DM
[2]. It will be important to determine if post-translational
modifications such as N-glycosylation are impaired in Type II
diabetes, and whether this results in a reduction in cell surface
GIPR and GLP-1R number along with the decreased incretin
response of the ß-cell. The finding that heteromerization between
GIPR and GLP1R can occur suggests that the much milder
reduction in GLP1 responsiveness could be a direct consequence
of the more profound and fundamental observed decrease in
GIPR expression. This possibility could explain the restoration of
responses to both incretins in diabetic patients in whom glucose
was almost normalized by insulin treatment [45]. Direct evidence
for heteromerization of GIPR and GLP1R in tissues such as the
pancreas would be an essential next step in determining the
potential physiological consequences, as well as the therapeutic
implications of such an interaction.
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